Cormorant Asset Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Cormorant Asset Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$62.4M	Sell	3,205,433 -1,275,000	-28%	-$23.1M	3.2%	12
2026 Q1	$83.5M	Buy	4,480,433 +125,000	+3%	+$2.07M	4.19%	9
2025 Q4	$57.4M	Buy	4,355,433 +2,361,260	+118%	+$27.9M	2.65%	13
2025 Q3	$14.3M	Sell	1,994,173 -6,499,978	-77%	-$339M	0.99%	25
2025 Q2	$401M	Hold	8,494,151	–	–	29.86%	1
2025 Q1	$332M	Hold	8,494,151	–	–	24.95%	1
2024 Q4	$460M	Hold	8,494,151	–	–	25.26%	1
2024 Q3	$428M	Hold	8,494,151	–	–	22.71%	1
2024 Q2	$373M	Hold	8,494,151	–	–	21.58%	1
2024 Q1	$427M	Hold	8,494,151	–	–	18.72%	1
2023 Q4	$513M	Buy	8,494,151 +352,051	+4%	+$18.1M	24.5%	1
2023 Q3	$464M	Hold	8,142,100	–	–	27.07%	1
2023 Q2	$415M	Buy	8,142,100 +1,249,999	+18%	+$33.6M	23.26%	1
2023 Q1	$147M	Buy	6,892,101 +827,100	+14%	+$13.9M	9.71%	2
2022 Q4	$63.7M	Hold	6,065,001	–	–	4.26%	4
2022 Q3	$47.1M	Hold	6,065,001	–	–	3.29%	6
2022 Q2	$30.9M	Buy	6,065,001 +2,785,001	+85%	+$17.5M	2.34%	11
2022 Q1	$33.3M	Buy	3,280,000 +2,850,000	+663%	+$28.4M	2.55%	14
2021 Q4	$4.25M	Hold	430,000	–	–	0.25%	57
2021 Q3	$4.28M	Hold	430,000	–	–	0.17%	72
2021 Q2	$4.45M	Hold	430,000	–	–	0.15%	84
2021 Q1	$4.39M	Hold	430,000	–	–	0.1%	98
2020 Q4	$4.74M	Buy	+430,000	New	+$4.57M	0.11%	88

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Cormorant Asset Management's MLTX Position: Q2 2026 in Review

Cormorant Asset Management reduced its MoonLake Immunotherapeutics (MLTX) stake by 28% in Q2 2026, selling an estimated $23.1M and leaving 3,205,433 shares worth $62.4M. The position accounts for 3.2% of the portfolio, ranked #12.

Cormorant Asset Management first reported a position in MLTX in Q4 2020 and has held it in 23 quarters since. The position peaked at $513M in Q4 2023. 172 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Cormorant Asset Management held 3,205,433 shares of MoonLake Immunotherapeutics worth $62.4M as of Q2 2026.
Cormorant Asset Management sold 1,275,000 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $23.1M.
MoonLake Immunotherapeutics made up 3.2% of Cormorant Asset Management's portfolio in Q2 2026, its #12 holding.
Cormorant Asset Management first reported a position in MoonLake Immunotherapeutics in Q4 2020 and has held it in 23 quarters since.
Cormorant Asset Management's MoonLake Immunotherapeutics position peaked at $513M in Q4 2023.
172 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Cormorant Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.